AT-101 is under clinical development by A28 Therapeutics and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase I drugs for Hepatocellular Carcinoma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AT-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AT-101 is under development for the treatment of solid tumors including prostate cancer, breast cancer, pancreatic cancer, endometrial cancer, ovarian cancer including peritoneal cancer, fallopian tube cancer, neuroendocrine tumors, hepatocellular carcinoma and immunotherapy. It is administered intravenously in the form of solution. The drug candidate is a peptide drug conjugate (PDC), consisting of LHRH receptor-targeting ligand conjugated to a membrane-disrupting peptide CLIP 71. It selectively targets the cell membranes of cancer cells which over-express the luteinizing hormone releasing hormone (LHRH) receptors. The drug candidate is developed based on cationic lytic peptide (CLYP) platform technology. It was also under development for blood cancer.
A28 Therapeutics overview
A28 Therapeutics is a clinical-stage biopharmaceutical company focused on the development of its targeted lytic peptide platform for the treatment of multiple cancer types. A28 Therapeutics is headquartered in La Jolla, California, the US.
For a complete picture of AT-101’s drug-specific PTSR and LoA scores, buy the report here.